Literature DB >> 7841019

Human placental calreticulin: purification, characterization and association with other proteins.

G Houen1, C Koch.   

Abstract

Calreticulin is an intracellular protein known to be involved in calcium binding, but is also known to appear as an autoantigen in certain autoimmune diseases. The cDNA sequence is known but the protein has not yet been well characterized at the amino acid level. Owing to the possible involvement of this protein in autoimmune disease and with the aim of making monoclonal antibodies for use in assay development and immunohistochemistry, we have purified calreticulin using human placental material. Amino acid analysis of the purified protein confirmed the cDNA-derived composition, and only one discrepancy between the cDNA-predicted sequence and the amino acid sequence was found by peptide mapping and microsequencing. The protein contains one disulfide bridge and has one free SH group and the protein is neither glycosylated nor phosphorylated. Affinity chromatography of a placental protein extract on a column with immobilized calreticulin showed the existence of at least six proteins interacting with calreticulin. Using the purified calreticulin in Western blots, two out of eight patients with autoimmune disease diagnosed as having anti DNA antibodies in their serum were found also to contain autoantibodies to calreticulin in their serum.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841019     DOI: 10.3891/acta.chem.scand.48-0905

Source DB:  PubMed          Journal:  Acta Chem Scand        ISSN: 0904-213X


  9 in total

1.  Structural Analysis of Calreticulin, an Endoplasmic Reticulum-Resident Molecular Chaperone.

Authors:  Gunnar Houen; Peter Højrup; Evaldas Ciplys; Christine Gaboriaud; Rimantas Slibinskas
Journal:  Prog Mol Subcell Biol       Date:  2021

2.  Characterization of calreticulin as a protein interacting with protein kinase C.

Authors:  E Rendón-Huerta; G Mendoza-Hernández; M Robles-Flores
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

3.  Immunological activity difference between native calreticulin monomers and oligomers.

Authors:  Mi-chun He; Jun Wang; Jian Wu; Fang-yuan Gong; Chao Hong; Yun Xia; Li-juan Zhang; Wan-rong Bao; Xiao-Ming Gao
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

4.  High-level secretion of native recombinant human calreticulin in yeast.

Authors:  Evaldas Čiplys; Eimantas Žitkus; Leslie I Gold; Julien Daubriac; Savvas C Pavlides; Peter Højrup; Gunnar Houen; Wen-An Wang; Marek Michalak; Rimantas Slibinskas
Journal:  Microb Cell Fact       Date:  2015-10-15       Impact factor: 5.328

Review 5.  Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin.

Authors:  Galia Ramírez-Toloza; Arturo Ferreira
Journal:  Front Microbiol       Date:  2017-09-01       Impact factor: 5.640

Review 6.  Is It Possible to Intervene in the Capacity of Trypanosoma cruzi to Elicit and Evade the Complement System?

Authors:  Galia Ramírez-Toloza; Lorena Aguilar-Guzmán; Carolina Valck; Smrithi S Menon; Viviana P Ferreira; Arturo Ferreira
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

7.  Self-oligomerization is essential for enhanced immunological activities of soluble recombinant calreticulin.

Authors:  Shang-Hui Huang; Li-Xiang Zhao; Chao Hong; Cui-Cui Duo; Bing-Nan Guo; Li-Juan Zhang; Zheng Gong; Si-Dong Xiong; Fang-Yuan Gong; Xiao-Ming Gao
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

Review 8.  Is the Antitumor Property of Trypanosoma cruzi Infection Mediated by Its Calreticulin?

Authors:  Galia Ramírez-Toloza; Paula Abello; Arturo Ferreira
Journal:  Front Immunol       Date:  2016-07-11       Impact factor: 7.561

Review 9.  The Interactions of Parasite Calreticulin With Initial Complement Components: Consequences in Immunity and Virulence.

Authors:  Galia Ramírez-Toloza; Lorena Aguilar-Guzmán; Carolina Valck; Viviana P Ferreira; Arturo Ferreira
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.